The peroxisome proliferator activated receptor c (PPARc) is a nuclear receptor highly expressed in the colon and playing a key role in bacterial induced inflammation. Regulation of colon inflammation by this receptor has been well demonstrated in many experimental models of colitis but also in patients with ulcerative colitis, characterised by impaired expression of PPARc confined to their colon epithelial cells. Recent data showing that PPARc was the major functional receptor mediating the common aminosalicylate activities in inflammatory bowel diseases (IBD) have also reinforced the roles of this receptor in the control of intestinal inflammation. The aims of this review are to discuss the potential roles of PPARc in the physiopathology of IBD, as well as the emerging therapeutic strategies targeting this receptor.
INTRODUCTION c
Current evidence suggests that Crohn's disease (CD) and ulcerative colitis (UC) result from a complex interplay between genetic and environmental factors, leading to an abnormal innate and adaptive immune response of the gut directed against luminal constituents in genetically determined patients. Identification of cytoplasmic receptors of bacterial peptidoglycan, namely nucleotide oligomerisation domain (NOD)2/caspase recruitment domain (CARD) 15 and NOD1/ CARD4, as CD susceptibility genes reinforced the pivotal role of the interactions between enteric microbes and the intestinal immune system in the physiopathology of IBD. [1] [2] [3] Furthermore, recent advances in our laboratory and others also indicate the involvement of another key receptor, PPARc, which regulates colon inflammation. This represents a new target in the development of therapeutic molecules in IBD.
PPARc is a nuclear receptor discovered in mammals in 1993 as an orphan receptor. 4 Until recently, PPARc was known as a receptor mainly expressed by adipose tissue and involved in the regulation of insulin resistance. PPARc is activated by antidiabetic thiazolidinedione drugs. 5 In 1998, the first studies were published reporting a potential link between this receptor and intestinal diseases, originally described in colon cancer [6] [7] [8] and one year later during intestinal inflammation. 9 There is now emerging interest in the roles of this receptor in the regulation of gut homeostasis. Using a computerised medical literature search of all English language articles selected from the ''PubMed'' online database with the keywords ''peroxisome proliferatoractivated receptor gamma'', ''inflammatory bowel disease'', ''Crohn's disease'', ''ulcerative colitis'', ''colitis'', ''ileitis'', and ''intestinal diseases'', more than 100 articles were found that reported a role for PPARc, mainly in colon cancer and intestinal inflammation.
After a brief presentation of PPARc and its ligands, the aims of this review are to outline the potential roles of PPARc in the physiopathology of IBD and highlight areas for future therapeutic strategies targeting this receptor.
PPARc STRUCTURE, EXPRESSION, AND REGULATION
PPARc structure and function PPARc belongs to the nuclear receptor family consisting of a group of approximately 50 transcription factors implicated in many different biological processes and considered as important targets in the development of new drugs. 10 PPARc is an essential nuclear receptor controlling the expression of a large number of regulatory genes in lipid metabolism and insulin sensitisation, as well as in inflammation and cell proliferation. 11 12 Its activation requires heterodimerisation in the nucleus of the cells with another nuclear receptor, known as the retinoid X receptor a (RXR a) (fig 1) , leading to binding of this heterodimer to specific DNA sequence elements termed peroxisome proliferator response elements (PPRE). 13 It has been demonstrated that these two nuclear factors play a central role in the regulation of inflammatory signalling pathways by acting on kinases and transcription factors, such as nuclear factor kB (NFkB), c-Jun, c-Fos, and nuclear factor of activated T cell (NFAT) 9 14 15 ( fig 2) and inhibiting mucosal production of inflammatory cytokines (interleukin (IL)-1b and tumour necrosis factor a (TNF-a)) 14 and chemokines, 16 proliferation of inflammatory cells, 17 and expression of some adhesion molecules (fig 2) . 18 PPARc is highly expressed in the colon High levels of PPARc expression have been reported in both colonic and adipose tissues. Originally described as a receptor expressed by adipose tissue where it plays a role in adipocyte differentiation and in the regulation of insulin responses, other tissues and cells are now known to express PPARc (fig 3) . 19 Among them, the colon is a major tissue expressing PPARc in epithelial cells and to a lesser degree macrophages and lymphocytes. [20] [21] [22] [23] [24] Microorganisms regulate PPARc expression in the colon PPARc is a modestly inducible receptor. Regulation of its expression remains poorly investigated although some reports suggest that it might be dependent at least in part on the cellular environment. In vivo, PPARc mRNA and protein levels are negatively regulated by long term hypocaloric diet, 25 fasting, and insulin deficient diabetes, 26 and positively by obesity and a diet rich in fatty acids. 25 26 More precisely, two classical pathways acting on PPARc expression have been commonly observed using adipocyte cell lines. Firstly, specific natural or synthetic ligands of PPARc can induce a mean 2-3-fold expression of this receptor in a positive feedback loop. 27 Secondly, different studies have demonstrated in vitro a synergistic effect of insulin and corticosteroids in inducing in vitro human PPARc expression by cultured adipocytes. 25 28 The NFkB and stress kinase pathways seem to be essential in post translational modifications of this nuclear receptor, but their regulatory effects on PPARc expression remain uncertain. Other factors involving growth hormone, 29 30 signal transducer and activator of transcription 5, 31 32 and insulin growth factor 1 33 have also been proposed in the regulation of PPARc expression, but these results need confirmation. 29 30 34 Recent research also indicates close links between intestinal-microbial interactions and regulation of PPARc expression by epithelial cells of the colon. To clarify the involvement of bacteria in the regulation of PPARc expression in vivo, we showed over expression of PPARc in the colon of mice with conventional or humanised flora compared with germ free animals. 22 Similarly, in vitro studies using HT-29 and/or Caco-2 colon epithelial cells or KatoIII gastric cells have demonstrated the ability of lipopolysaccharide (LPS), 22 35 Saccharomyces boulardii, 36 and Helicobacter pylori 37 These results were confirmed in vitro after transfection of Caco-2 cells with the constitutively active form of TLR4 leading to a fourfold induction of PPARc expression (fig 4) . 22 An alternative way to regulate PPARc expressed by epithelial cells through bacteria might be production of the volatile fatty acid butyrate produced by commensal intestinal flora. In contrast with other short chain fatty acids such as propionate or valerate, butyrate 2 mM caused a two-and sevenfold increase in PPARc protein expression, respectively, after three and seven days of incubation of Caco-2 epithelial cells. 38 Taken together, these results indicate the pivotal role of bacteria in the regulation of PPARc expression by epithelial cells, which might account for the characteristic and important PPARc pattern expression in the colon compared with other parts of the digestive tract. Although all microorganisms probably do not have the same ability to induce PPARc expression, it seems that LPS of Gram negative bacteria are critical in colonic steady state PPARc expression through TLR4. Studies are now in progress to evaluate the capacity of commensal bacteria to induce PPARc expression and activation and to use this property as a criterion for probiotic selection.
NATURAL AND SYNTHETIC LIGANDS OF PPARc
Natural ligands Many natural endogenous lipophilic species such as the polyunsaturated fatty acids (PUFAs) 39 and eicosanoids 40 are classically proposed as natural PPARc ligands (table 1) . However, their intrinsically low binding affinities and weak in vivo concentrations in intestinal cells do not support physiological functions of many of these compounds.
Although many PUFA activate PPARc in micromolar amounts and are recorded as functional in human plasma at these concentrations, 39 their in vivo intestinal effects through PPARc activation remain hypothetical as concentrations of these fatty acids within colonic cells are unknown. Recently, two studies performed by the group of BassaganyaRiera et al demonstrated that, in contrast with a mixture of eicosapentaenoic and docohexaenoic acids, food supplemented with conjugated linoleic acid (CLA) efficiently prevents the development of colitis in pigs and mice. 50 51 Moreover, they confirmed the direct involvement of PPARc in the mechanism of action of CLA using colonic PPARc null mice obtained by a Cre-lox recombination system. 51 Chemically, CLA is a mixture of four isomers (cis-9, cis-10, trans-11, and trans-12) of linoleic acid with both distinct biological properties. As CLA is mainly found in milk and meat products and may also be generated from linoleic acid by human gut microflora, 52 these studies are important, identifying for the first time that PPARc natural ligands present in food or synthesised by commensal flora may improve colon inflammation. The eicosanoid 15-deoxy-prostaglandin J2 (15d-PGJ2) is also proposed as a natural ligand of PPARc. 40 Preventive intravenous administration of high doses of 15d-PGJ2 (0.3 mg/kg) reduces ileal injury and mortality induced by intestinal ischaemia and reperfusion in rats. 53 However, the physiological role of 15d-PGJ2 in PPARc activation in the colon is still open for debate as minimal concentrations of 15d-PGJ2 required to activate PPARc are approximately 10-150-fold higher that those found in human intestinal epithelial cells. 54 Recently, the unsaturated fatty acid derivative nitrolinoleic acid (LNO 2 ), generated via nitric oxide dependent oxidative inflammatory reactions, has been identified as a new PPARc agonist. 43 Present in the vascular cell wall as the most abundant bioactive oxide of nitrogen and in the blood of healthy individuals at concentrations of approximately 500 nM, LNO 2 is considered at present to be one of the most potent physiological endogenous natural ligand of PPARc. It Figure 2 Interferences of peroxisome proliferator activated receptor c (PPARc) with inflammatory signalling pathways. PPARc inhibits nuclear factor kB (NFkB) signalling pathway through interactions with NFkB, the inhibitory protein called IkB, and CBP, a coactivator of p65. The MAPK pathway is also regulated by PPARc, which reduces JNK and p38 activation and inhibits the transcription factors c-jun, c-fos, and nuclear factor of activated T cell (NFAT). Regulation of these main signalling pathways results in inhibition of cytokine and chemokine production, cell proliferation, and adhesion molecule expression (mainly VCAM-1), which decrease inflammatory cell recruitment in inflamed tissues. 15dPGJ2, 15-deoxy-D12,14-prostaglandin J2; PUFAs, polyunsaturated fatty acids; 5-ASA, 5-aminosalicylic acid. works at nanomolar concentrations and displays 10-fold more efficacy than other known natural ligands such as lysophosphatidic acid, isomers of CLA, and 15d-PGJ2. 43 If LNO 2 seems interesting in vascular diseases, future studies are needed to determine its intestinal effects in the maintenance of gut homeostasis and during inflammatory disorders.
Synthetic ligands
PPARc has a large ligand binding pocket that accommodates lipophilic ligands, belonging to several different groups of chemical compounds such as thiazolidinediones, also known as glitazones which bind selectively PPARc, and glitazars which bind both PPARa and PPARc. Troglitazone was the first glitazone developed for therapeutic use in patients with diabetes and withdrawn from the market due to severe hepatic toxic effects. After demonstration that liver injury of troglitazone was idiosyncratic and independent of PPARc stimulation, numerous additional glitazone molecules have been developed and two are already approved in the treatment of type 2 diabetes (rosiglitazone-avandia and pioglitazone-actos) (table 2). Glitazar is a novel family of dual acting PPARa/c agonists developed as an oral treatment for insulin resistance related glucose and lipid abnormalities associated with type 2 diabetes and the metabolic syndrome. 55 Four glitazar molecules have been developed and are awaiting FDA approval (table 2) . Non-steroidal anti-inflammatory drugs are also reported in vitro as PPARc ligands but in vivo their binding affinities of 0.1 mM are 1000-fold higher than the mean concentrations found in patients conventionally treated with these drugs (table 2) . 56 To date, only one open label pilot trial has evaluated the efficacy of the PPARc ligand rosiglitazone (4 mg orally twice daily) in 15 patients with active UC, refractory to conventional treatment with either corticosteroids or immunomodulators and 5-aminosalicylic acid. 69 After 12 weeks of treatment with rosiglitazone, a substantial decrease in disease activity index score was reported, with clinical and endoscopic remission (27% and 20%, respectively) or part response (27%) in eight patients. 69 Due to their systemic effects, the most well known adverse events of thiazolidinediones observed in patients with diabetes are weight gain and infrequent hepatotoxicity. This study in IBD patients led to new clinical trials in IBD with these chemical compounds, and may lead to the development of safer PPARc agonist with topical effects and targeting selectively the colon. 64 5-ASA is one of the oldest antiinflammatory agents in use for the treatment of IBD, but the mechanism underlying its intestinal effects remains unknown. We showed that chemically induced colitis in mice heterozygous at the PPARc locus (PPARc +/2) was refractory to 5-ASA therapy, arguing for a major role of PPARc in mediating in vivo the anti-inflammatory effect of 5-ASA in the gut. Using the HT-29 colon epithelial cell line, we found that 5-ASA induced PPARc expression. 5-ASA was also able to bind PPARc, to induce its translocation from the cytosol of epithelial cells to the nucleus, to promote a PPARc conformational change, and to recruit a coactivator named DRIP ( fig 5) . Docking simulations showed a binding mode of 5-ASA very similar to the crystal orientation of the 6) . 64 Taken together, these data show that PPARc is an essential receptor mediating the common 5-ASA activities in IBD.
5-Aminosalicylic acid (5-
ASA): a prototype of a new class of PPARc agonists Recently, we published studies showing functional, biological, pharmacological, and chemical evidence that aminosalicylates are a new functional synthetic ligand for PPARc in colonic epithelial cells.1 Affinity and physiological roles of natural peroxisome proliferator activated receptor c (PPARc) modulators Modulators EC50
PPARc IN IBD
PPARc and experimental models of colitis The first evidence of the involvement of PPARc in the regulation of intestinal inflammation came from the use of the PPARc synthetic agonist thiazolidinedione in mice with colitis induced by oral administration of dextran sodium sulfate (DSS). 9 In this study, the two thiazolinediones troglitazone and rosiglitazone dramatically reduced disease severity in mice with colitis from 47% to 70%, seven days after DSS administration compared with the placebo treated group. These results were confirmed and extended several months later in another model of experimental colitis induced in mice by intrarectal administration of 2,4,6-trinitrobenzene sulfonic acid (TNBS). Thiazolidinediones given preventively or in treatment mode have a therapeutic effect, reducing mortality, intensity of macroscopic and histological lesions, and levels of biological markers of colon inflammation, including the NFkB and stress kinase pathways involved in transduction of inflammation. 14 In addition, genetic involvement of PPARc in the protection against colon inflammation was shown by the increased susceptibility of PPARc heterozygous mice (PPARc +/ 2 ) to TNBS induced inflammation compared with their wildtype littermates.
14 At the present time, more than 20 published studies have reported similar prophylactic and therapeutic effects of PPARc in different strains of mice, rats, or pigs with acute colitis induced by chemical compounds, 9 14 bacteria, 50 ischaemia-reperfusion, 70 and also in chronic colitis occurring after the transfer of immunocompetent T cells in SCID mice 51 or spontaneously in IL-10 deficient mice 71 and SAMP1/YitFc animals (table 3). 72 Lessons from these animal studies are numerous. Firstly, natural and synthetic ligands of PPARc are both effective in the treatment of acute and chronic colitis, with a similar beneficial effect of CLA and thiazolidinediones. Secondly, even if these treatments are efficacious when they are administered preventively or in treatment mode, a prophylactic effect is always more pronounced suggesting that PPARc agonists may have higher efficacy in maintenance than in induction treatment in IBD patients. Thirdly, the therapeutic effect of PPARc is mainly dependent on its abundance in target tissues. This notion is supported by the different susceptibility to colitis of animals in which the PPARc gene has been disrupted 14 51 or enhanced through gene transfer using adenoviruses, 73 and also by analysis of SAMP1/YitFc animals where specific impaired expression and activation of PPARc in the crypts of the small intestine is associated with ileitis. 72 As PPARc is expressed in the colon by epithelial cells and lamina propria mononuclear cells such as macrophages, and T and B cells, additional investigations in animals with cell type specific expression of PPARc are required to determine the main cellular source responsible for the therapeutic effect of PPARc.
PPARc in patients with ulcerative colitis and Crohn's disease Despite in vitro and in vivo evidence of the anti-inflammatory functions of the PPARc/RXR heterodimer in the colon, very few studies have assessed the role of PPARc in UC and CD. 22 69 72 As PPARc is mainly expressed in the colon by epithelial cells, prior expectation might be that decreased expression of this receptor may be found in an inflammatory disorder confined to superficial layers of the intestine and limited to the colon, such as UC rather than CD. Using quantitative polymerase chain reaction, ribonuclease protection assay, western blot, and imuunohistochemical methods, 60% decreased expression of PPARc was observed at the mRNA and protein levels in the colon of UC patients compared with patients with CD and controls. 22 This impaired expression was found in both healthy and inflamed colon and was limited to epithelial cells, suggesting that perturbed levels of PPARc in UC are not secondary to the inflammatory process. The aetiology underlying impaired PPARc expression in colonic epithelial cells of UC patients remains unknown. Comparable levels of PPARc in peripheral mononuclear cells of IBD patients and controls and absence of specific mutations of the PPARc gene or its promoter in UC patients suggest that epigenetic events may account for impaired PPARc expression in UC patients. 22 Another attractive 72 Replication of these results in independent cohorts of patients, family based analyses, and genotype/phenotype correlation studies will be necessary to conclude more definitely that PPARc is a susceptibility gene in CD.
CONCLUSION AND PERSPECTIVES
PPARc is highly expressed in the colon and a key receptor in the regulation of intestinal inflammation induced by bacteria. Other studies also indicate a role of PPARc in tumour suppression, particularly in colon cancer. [6] [7] [8] Therefore, greater knowledge of PPARc expression and function in intestinal homeostasis and during inflammation will fuel speculations about its potential therapeutic effects in IBD to prevent inflammation and colorectal cancer. 81 The discovery that 5-ASA is a new topical ligand for this receptor expressed by colonic epithelial cells paves the way for the development of new molecules specifically targeting intestinal PPARc. Because 5-ASA was originally developed without any prior knowledge of its molecular target, there is hope that the research described above will lead to rationale optimisation or development of better PPARc ligands. To date, 20 new molecules have been developed, optimised by docking analysis to activate PPARc in intestinal epithelial cells. Among them, two families of compounds have been selected having 30-50-fold more efficacy than 5-ASA in activating PPARc (personal communication). Optimisation of these new molecules is now in progress. Improvements in efficacy and safety may reside not solely in new compounds with higher affinity but also in a combination of agents with additive or synergic effects on PPARc/RXR heterodimer. In this way, studies showing the synergistic effects of PPARc and RXR agonists must be considered.
14 Furthermore, of considerable interest is the recent discovery that some commensal bacteria and natural ligands present in food may induce PPARc expression and activation in the colon. These data suggest the potential of associating a natural regulator and a synthetic ligand of PPARc as drug therapy for IBD patients. N Updating the text every 12 months using any new, sound evidence that becomes available.
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